AACR-II 2020 - American Association of Cancer Research (Virtual Meeting II)
Jun 22 - Jun 24, 2020 | San DiegoCAUS
LARVOL is not affiliated with American Association of Cancer Research (Virtual Meeting II) and all trademarks, logos, and brand names are property of their respective owners
Showing 236 abstracts linked to Trials
1843/15 - [VIRTUAL] Melflufen efficacy in multiple myeloma with TP53 aberrations
5588/21 - [VIRTUAL] Clinical and pharmacodynamic responses to a modified whole tumor cell immunotherapy in patients with advanced breast cancer from two phase I-IIa trials
5201/27 - [VIRTUAL] U3-1402, a novel HER3-targeting antibody-drug conjugate, exhibits in vitro antitumor activity against breast cancer cells expressing HER3 mutations without dependence on HER2 overexpression
5398/11 - [VIRTUAL] Analysis of tumor microenvironmental features to refine prognosis in patients with stage III colon cancer (NCCTG N0147, Alliance)
1998/6 - [VIRTUAL] Predictive and prognostic role of T- and B-cell receptor repertoire in HER2-positive breast cancer: An analysis of the NeoALTTO clinical trial
2009/17 - [VIRTUAL] Evaluation of RNA-sequencing signatures with response to pembrolizumab (pembro) monotherapy in ipilimumab-naive patients (pts) with melanoma
2011/19 - [VIRTUAL] HER2 expression and M2-like tumor infiltrating macrophages associated with Cabazitaxel activity in gastric cancer
2017/25 - [VIRTUAL] Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients
2019/27 - [VIRTUAL] Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)
766/3 - [VIRTUAL] Clinical outcomes of patients with PIK3CA mutations in circulating tumor DNA: Update from the MONARCH 2 study of abemaciclib plus fulvestrant
776/13 - [VIRTUAL] Androgen receptor (AR) and non-AR aberrations associated with outcomes in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN
779/16 - [VIRTUAL] A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort
1273/26 - [VIRTUAL] RASSF1 promoter hypermethylation is associated with activated CTNNB1 pathways in hepatocellular carcinoma
784/21 - [VIRTUAL] Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)
785/22 - [VIRTUAL] Genomic markers of response to monotherapy abemaciclib in the nextMONARCH 1 study